(MEER-veh-TUK-sih-mab SOH-rav-TAN-seen)
This page contains brief information about mirvetuximab soravtansine-gynx and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Mirvetuximab soravtansine-gynx is approved to treat:
- Ovarian epithelial, fallopian tube, or primary peritoneal cancer that is folate receptor–alpha positive. It is used in adults whose cancer did not respond to or is no longer responding to platinum chemotherapy and who have received one to three types of systemic therapy.
Mirvetuximab soravtansine-gynx is also being studied in the treatment of other types of cancer.
More About Mirvetuximab Soravtansine-gynx
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Mirvetuximab Soravtansine – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
